The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Future frontline Hodgkin lymphoma strategies aim to reduce treatment toxicity
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the future of frontline Hodgkin lymphoma treatment, emphasizing the importance of reducing long-term toxicities while maintaining high cure rates. He explores the growing role of response-adapted strategies, cell-free DNA (cfDNA) analysis, and the potential move toward less chemotherapy-intensive or even chemotherapy-free approaches. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
